← Back to Search

Virus Therapy

FLT201 for Gaucher Disease

Phase 1 & 2
Recruiting
Research Sponsored by Freeline Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
n/a
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 38 to month 60
Awards & highlights

Summary

This trial will follow participants with Gaucher disease type 1 who were previously treated with FLT201 in a different trial. The participants will be monitored for 5 years after the treatment.

Who is the study for?
This trial is for individuals with Type-1 Gaucher Disease who have previously received FLT201 treatment in an earlier study. They will be monitored over a period of 5 years to understand the long-term effects of the treatment.
What is being tested?
The trial is observing the long-term outcomes and safety of FLT201, a therapy for Type-1 Gaucher Disease, by following participants from a previous clinical study over five years after their last dose.
What are the potential side effects?
Since this is a follow-up study, specific side effects are not listed; however, it will monitor any long-term health changes that may relate to prior FLT201 treatment.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
N/A

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 38 to month 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 38 to month 60 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of treatment-emergent adverse events (TEAEs) (including DLTs)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dosed with FLT201Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Freeline TherapeuticsLead Sponsor
6 Previous Clinical Trials
77 Total Patients Enrolled
1 Trials studying Gaucher Disease
18 Patients Enrolled for Gaucher Disease
~50 spots leftby May 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top